Is AOD-9604 Legal in Pennsylvania? How to Access It Legally

AOD-9604 (also written AOD9604) is a synthetic 15-amino-acid fragment of human growth hormone, corresponding to amino acids 177 to 191 of the hGH molecule. It is not a brand-name drug, not an approved obesity medication, and not the same molecule as full-length human growth hormone. It has never received FDA approval as a finished drug product, and it is not scheduled as a controlled substance by the DEA.

The useful question for a Pennsylvania resident is not simply "is it legal," because the honest answer has two layers. Federally, AOD-9604 sits in a compounding gray zone: it can lawfully be compounded by a licensed pharmacy for a specific patient under certain conditions, but it is not an approved commercial product you can legally buy off a shelf or from an unregulated online seller. In Pennsylvania specifically, whether a given transaction is lawful depends less on the peptide itself and more on whether the prescriber, the pharmacy, and the telehealth encounter each meet existing legal requirements. A person can obtain AOD-9604 through a technically "legal" seller and still be participating in a chain that skips a required step.

AOD-9604 is not FDA-approved and not federally scheduled as a controlled substance; a Pennsylvania-licensed physician, physician assistant, or nurse practitioner may prescribe it as a compounded preparation from a 503A pharmacy when a documented patient-specific need exists, but buying it without a prescription, importing it from overseas, or receiving a prescription without a genuine clinical encounter falls outside both federal compounding law and Pennsylvania's telehealth standard of care. This is the core fact pattern that determines legal access in the state as of 2025.

What AOD-9604 is, and what it is not

AOD-9604 was developed by Metabolic Pharmaceuticals in Australia and studied through Phase III clinical trials for obesity. The design intent was to isolate the fat-metabolizing (lipolytic) region of the hGH molecule while leaving out the region responsible for raising IGF-1 and driving the insulin resistance associated with full-length growth hormone therapy. It reached Phase III testing in an oral formulation; public reporting on the program describes weight-loss results that did not meet the sponsor's threshold for commercial development, and Metabolic Pharmaceuticals did not submit a New Drug Application to the FDA. A separate, smaller program explored an injectable form and an intra-articular use in osteoarthritis; neither reached approval.

Because the program never advanced to an approved product, and because AOD-9604 was never placed on a controlled substance schedule, it has continued to circulate through two very different channels: legitimate compounding pharmacies filling patient-specific prescriptions, and unregulated "research chemical" sellers with no prescription requirement at all. Those two channels have very different legal standing, which is the core distinction this page addresses.

Evidence boundary on efficacy and safety: The existence of Phase III trials is well documented publicly, but the specific numeric results, sample sizes, and safety findings from those trials are not independently re-verified in the source material available for this draft. Readers and clinicians should treat any specific percentage, sample size, or lab-value claim about AOD-9604's trial data as requiring direct verification against the original trial publications or FDA/sponsor records before being relied upon. This article deliberately avoids restating unverified numeric trial results.

Federal status: three separate questions

Understanding AOD-9604's status requires separating three distinct legal questions that are often conflated.

Is it a controlled substance? No. As of this writing, AOD-9604 does not appear on DEA Schedules I through V (DEA drug scheduling). Absence from scheduling is not the same as being legal to manufacture, sell, or distribute; it simply means possession does not carry the criminal penalties attached to scheduled substances. Confirm current scheduling status directly with DEA resources, since schedules are periodically updated.

Is it an FDA-approved drug? No. No finished drug product containing AOD-9604 has been approved under 21 U.S.C. §355. Selling or distributing an unapproved new drug in interstate commerce is prohibited, which is the legal basis the FDA has reportedly used in warning letters to companies marketing unapproved peptide products, including some sold as "research use only". Labeling a product "not for human use" does not exempt a seller from this framework if the product is being marketed for human consumption.

Can it be legally compounded? Potentially, and this is where most of the real-world legal activity happens. The Drug Quality and Security Act of 2013 created two compounding frameworks:

• Section 503A allows a licensed pharmacy to compound a preparation for a named patient based on a valid, patient-specific prescription, if the bulk substance is on the FDA's 503A Bulks List or is a component of an FDA-approved drug. AOD-9604's placement on that list should be verified directly with the current FDA bulk substance list, since nomination and review status changes over time and this draft cannot state a confirmed, dated determination.
• Section 503B covers outsourcing facilities that produce larger batches without patient-specific prescriptions, under stricter manufacturing standards and a separate, more restrictive bulk substances list. AOD-9604 is not understood to be on the finalized 503B list, which is why most legitimate access runs through 503A patient-specific compounding rather than 503B outsourcing.

The practical effect: a pharmacy's willingness to compound AOD-9604 under 503A reflects that pharmacy's own compliance judgment about an evolving bulk-substance status, not a blanket FDA endorsement of the peptide.

Pennsylvania-specific rules

Pennsylvania does not maintain a separate state list of banned or restricted peptides beyond federal law. The Pennsylvania State Board of Pharmacy, operating under Title 49 Pa. Code Chapter 27 and the Pharmacy Act (63 P.S. §§390-1 et seq.), regulates who may compound and dispense, not which specific peptides are named. A compounded preparation that is defensible under federal 503A standards and prepared by a Pennsylvania-licensed pharmacy is dispensable to a Pennsylvania patient (PA Board of Pharmacy).

Sterile compounded injectables, which includes an AOD-9604 subcutaneous preparation, fall under USP Chapter <797> sterile compounding standards. Pennsylvania inspects compounding pharmacies against this standard, and a pharmacy that fails sterility or beyond-use-date requirements can lose its compounding authority.

Under the Pennsylvania Medical Practice Act (63 P.S. §422.1 et seq.), physicians have broad authority to prescribe compounded preparations off-label when clinically appropriate for an individual patient, and physician assistants and certified registered nurse practitioners may prescribe within their respective practice agreements. Off-label prescribing itself is legal; the FDA has long recognized that a licensed practitioner may prescribe an approved or compounded product for a use not covered by any formal labeling, based on individual clinical judgment, consistent with longstanding FDA policy on off-label use.

Pennsylvania is a member of the Interstate Medical Licensure Compact, which lets physicians licensed in other compact states obtain expedited Pennsylvania licensure. A telehealth prescriber based elsewhere can hold a genuine Pennsylvania license and prescribe legally to a Pennsylvania patient. Pennsylvania's telehealth law (Act 20 of 2023) requires that a telehealth encounter meet the same standard of care as an in-person visit, including a documented history, review of contraindications, and a follow-up plan. A prescription generated from a brief online questionnaire with no synchronous clinical encounter does not meet this standard, regardless of where the prescriber is licensed.

A Pennsylvania access-pathway decision framework

The legal risk in obtaining AOD-9604 in Pennsylvania depends almost entirely on which of these pathways a given seller or provider is using. This is not a ranking of quality; it is a map of what is defensible under current federal compounding law and Pennsylvania practice rules, versus what is not.

Three questions worth asking before paying anyone, regardless of how the offer is presented:

1. Did a licensed clinician actually see or speak with me before prescribing, and can I verify their Pennsylvania license through the Department of State lookup?
2. Is the compounding pharmacy 503A-licensed, and is that license current and specific to sterile compounding?
3. Was I given baseline evaluation and a follow-up plan, or just a payment page and a shipping form?

If the answer to any of these is no, the pathway is either legally exposed, clinically unsupervised, or both.

What clinical evidence does and does not establish

Established: AOD-9604 completed Phase III human trials for obesity in an oral formulation and did not advance to FDA approval. It is not a controlled substance. It is chemically distinct from full-length hGH.

Plausible but requiring verification: Claims that injectable AOD-9604 avoids IGF-1 elevation and insulin resistance seen with full hGH are consistent with the peptide's designed mechanism and are commonly cited in secondary and clinical-practice sources, but the specific published data supporting this at the doses used in current compounding practice should be verified against the primary trial literature before being presented to a patient as an established safety finding.

Not established: There is no FDA-reviewed evidence base demonstrating that compounded, self-injected AOD-9604 at the doses commonly used in telehealth weight-management practice produces clinically meaningful, reproducible fat loss in humans. The oral Phase III program is the most substantial human trial evidence and did not lead to approval. Any specific numeric efficacy or purity statistic circulating online (including claims about contamination rates in unregulated peptide products) should be treated as unverified unless traced to a specific, checkable publication.

What is clearly not a legal pathway

• Buying from unregulated online sellers. Vendors marketing AOD-9604 as a "research chemical" for human use are outside FDA authorization and have been the subject of FDA warning letters targeting unapproved peptide products generally. Purchasing from them is not a criminal act under Pennsylvania law, since the peptide is unscheduled, but the product carries no verified sterility, dosing accuracy, or identity assurance.
• Importing from abroad. This falls under FDA's authority to detain or refuse unapproved drugs at the border (21 U.S.C. §381). Personal-importation exceptions generally do not apply to unapproved new drugs.
• Questionnaire-only telehealth prescriptions. These do not satisfy Pennsylvania's Act 20 standard-of-care requirement for a telehealth encounter and may be treated by the Board of Pharmacy as prescriptions issued without a valid patient-provider relationship.

Choosing a provider in Pennsylvania

Ask directly:

• Does the platform require a real-time video or phone visit before prescribing, rather than a form alone?
• Does the prescriber hold a verifiable, active Pennsylvania medical, PA, or CRNP license (checkable through the PA Department of State license lookup)?
• Does the platform use a named, PA-recognized 503A compounding pharmacy rather than an unnamed "partner lab"?
• Are baseline labs reviewed, and is there a documented follow-up point, typically in the 4 to 6 week range, before renewal?

A provider or platform that cannot answer these plainly is either operating outside Pennsylvania's telehealth standard of care, working with a pharmacy of uncertain compliance status, or both. This is a judgment call for the reader and their clinician, not a guarantee of safety.

When to seek care rather than self-manage

This information does not substitute for individualized medical advice. A clinician should evaluate any new injectable therapy in the context of your full health history, medications, and metabolic status before a prescription is written, and dosing decisions belong to that clinician, not to general practice patterns described here. Seek prompt medical attention for signs of an allergic reaction, significant injection-site infection, unexplained severe fatigue, or any new symptom that concerns you after starting a compounded peptide, and stop the medication until you have spoken with your prescriber.